Physician profile
Stacey Knox
NPI 1750353447
$1,457.84
in general payments reported to CMS, 2019-2025
28 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.32 · 2020: $97.15 · 2021: $254 · 2022: $244 · 2023: $443 · 2024: $192 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $763.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $260.65 | 2019-2025 | Opdualag, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $175.57 | 2021-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $137.86 | 2022-2025 | |
| Celgene Corporation | $135.04 | 2021-2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $86.48 | 2022-2023 | |
| Array Biopharma INC | $82.76 | 2022-2023 | Braftovi, Lorbrena, Mektovi |
| Daiichi Sankyo INC. | $55.51 | 2020-2023 | Enhertu |
| Emd Serono, INC. | $55.12 | 2021-2023 | Bavencio |
| Cti Biopharma Corp. | $48.08 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $45.00 | 2019-2024 | Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $41.81 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $39.71 | 2023 | Fotivda |
| Eisai INC. | $36.53 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $36.35 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.86 | 2020-2023 | Iclusig |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.39 | 2025 | Enhertu |
| Seagen INC. | $22.90 | 2022 | |
| Verity Pharmaceuticals INC. | $20.83 | 2023 | Trelstar |
| Morphosys, US INC. | $20.73 | 2021 | |
| Incyte Corporation | $18.66 | 2020 | |
| Agios Pharmaceuticals, INC. | $18.14 | 2023 | Pyrukynd |
| Exelixis INC. | $14.60 | 2025 | Cabometyx |
| Adaptive Biotechnologies Corporation | $13.46 | 2024 | Clonoseq |
| Novocure INC. | $12.87 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.01 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.